Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proposal to decrease the risk and improve the prognosis of breast cancer.

R D Gambrell

    American Journal of Obstetrics and Gynecology
    |September 15, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Moderate dosage estrogen-androgen therapy improves continuation rates in postmenopausal women: impact of the WHI reports.

    Climacteric : the journal of the International Menopause Society·2006
    Same author

    Physicians should provide moral leadership to their communities: Presidential address.

    American journal of obstetrics and gynecology·2000
    Same author

    Estrogen replacement therapy in women with previous breast cancer.

    American journal of obstetrics and gynecology·1999
    Same author

    Strategies to reduce the incidence of endometrial cancer in postmenopausal women.

    American journal of obstetrics and gynecology·1997
    Same author

    Hormone replacement therapy and breast cancer risk.

    South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie·1996
    Same author

    Hormone replacement therapy and breast cancer risk.

    Archives of family medicine·1996
    Same journal

    Likelihood ratios enhance clinical interpretation of metagenomic prediction of early-onset neonatal sepsis in preterm premature rupture of membranes (Letter-to-the-Editor).

    American journal of obstetrics and gynecology·2026
    Same journal

    Taking risk stratification in preterm premature rupture of membranes to the bedside (Reply to Letter-to-the-Editor).

    American journal of obstetrics and gynecology·2026
    Same journal

    Gestational Age at Full-Term Delivery and Long-Term Offspring Morbidity in Low-Risk Pregnancies: A Population-Based Cohort Study.

    American journal of obstetrics and gynecology·2026
    Same journal

    Trajectories of childbirth-related posttraumatic stress symptoms after a vaginal delivery: a multicenter prospective study.

    American journal of obstetrics and gynecology·2026
    Same journal

    Early life adversity and polycystic ovary syndrome among North American pregnancy planners.

    American journal of obstetrics and gynecology·2026
    Same journal

    Survival assessment of adjuvant chemotherapy for cytology-negative, non-myoinvasive stage IC clear cell endometrial cancer.

    American journal of obstetrics and gynecology·2026
    See all related articles

    Hormone therapy, particularly estrogen-progestogen use, was associated with significantly lower breast cancer mortality and incidence. This suggests hormone replacement therapy may reduce breast cancer risk and improve survival rates.

    Area of Science:

    • Oncology
    • Endocrinology
    • Epidemiology

    Background:

    • Hormone replacement therapy (HRT) use has been a subject of debate regarding its impact on breast cancer.
    • Previous studies have yielded conflicting results on the relationship between HRT and breast cancer risk and outcomes.

    Purpose of the Study:

    • To investigate the association between hormone therapy use and breast cancer mortality and incidence.
    • To evaluate the effect of estrogen and progestogen on breast cancer risk and survival rates.

    Main Methods:

    • Retrospective cohort study of 256 breast cancer patients diagnosed between 1972 and 1981.
    • Analysis of mortality rates, axillary node status, and 5-year survival rates in hormone users versus nonusers.
    • Prospective phase (1975-1981) to assess breast carcinoma incidence in relation to hormone use.

    Related Experiment Videos

    Main Results:

    • Hormone users exhibited significantly lower mortality (22.2%) compared to nonusers (45.5%).
    • The 5-year survival rate for hormone users was higher (76.2%) than for nonusers (48.1%).
    • Estrogen-progestogen users showed the lowest breast carcinoma incidence (67.3:100,000), significantly lower than untreated groups.

    Conclusions:

    • Estrogen therapy alone did not appear to increase breast cancer risk.
    • The addition of progestogen to estrogen therapy significantly decreased the risk of breast cancer.
    • Hormone therapy, specifically estrogen-progestogen combinations, may be associated with reduced breast cancer incidence and improved patient outcomes.